NCT03237780 2026-03-18
Atezolizumab With or Without Eribulin Mesylate in Treating Patients With Recurrent Locally Advanced or Metastatic Urothelial Cancer
National Cancer Institute (NCI)
Phase 2 Active not recruiting
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Aarhus University Hospital
Swiss Cancer Institute
Memorial Sloan Kettering Cancer Center
Memorial Sloan Kettering Cancer Center
Hoosier Cancer Research Network
Fundacion Oncosur